Medication info
Rosuvastatin Calcium 10mg Tablets

Rosuvastatin Calcium 10mg Tablets

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
GL Pharm Co., Ltd.
Appearance
Pink, round, film-coated tablet
Packaging
PTP - 28 tablets/PTP
Approval status
Active

MFDS item code 201904447 · Approved 2019.06.28 · Insurance code 649702260

Summary

Main use
Improvement of dyslipidemia; slowing of atherosclerosis progression; prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients.
Children's dosage
Ages 10–17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
GL Pharm Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia; slowing of atherosclerosis progression; prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for various diseases associated with hypercholesterolemia. It is primarily prescribed as an adjunct to diet for patients with primary hypercholesterolemia and mixed dyslipidemia that are not controlled by diet and exercise. It also helps in the treatment of patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia. In particular, it may be prescribed for children aged 10 to 17 years with heterozygous familial hypercholesterolemia who meet specific criteria, lowering total cholesterol and LDL cholesterol levels. This medication delays the progression of atherosclerosis and reduces the risk of stroke, myocardial infarction, and revascularization procedures in high-risk patients, thus effectively treating hypercholesterolemia and related cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 3. Older adults: No dosage adjustment is necessary. 4. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this drug is contraindicated in some of these patients.

Children's dosage

Ages 10–17 years: The usual dosage range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy have not been established.

Precautions

This medication should not be administered to certain patients. For instance, it should not be used in patients who are allergic to it, have severe liver dysfunction, have muscle diseases, are taking certain immunosuppressants, have severe renal impairment, are pregnant or breastfeeding, and in fertile women who do not use adequate contraception. Additionally, the high-dose administration of this medication is prohibited for patients with a high risk of myopathy or rhabdomyolysis. Risk factors include moderate renal impairment, hypothyroidism, family history of muscle disease, and alcohol abuse. This medication contains lactose, so patients with lactose intolerance or related genetic disorders should avoid it. Caution should be exercised when administering this medication to patients with abnormal liver function or those who consume alcohol excessively, and it is advisable to repeat liver enzyme tests before and during treatment. If symptoms such as myalgia, muscle weakness, or cramps occur, inform healthcare professionals immediately, and if necessary, check for muscle damage through blood tests. If symptoms are severe or blood test values are high, medication administration may need to be discontinued. Caution is also necessary for patients with acute severe illness or at risk of worsening renal failure, and the administration should be stopped if severe myasthenia gravis or ocular myasthenia occurs. This medication may interact with other drugs; therefore, it should be used with caution, especially when combined with specific antivirals, immunosuppressants, antifungals, antibiotics, and fibrates, as the risk of muscle damage may increase. Women who are pregnant or breastfeeding should not use this medication, and fertile women must ensure adequate contraceptive measures. In cases of overdose, there is no specific antidote, so treatment should be symptomatic, including liver function and muscle enzyme tests. Dizziness may occur during medication use; thus, caution should be observed when driving or operating machinery. Finally, rare but serious skin reactions, liver damage, neurological symptoms, and muscle inflammation may occur, so if any abnormal symptoms appear, consult healthcare professionals immediately.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, drug rash resembling psoriasis, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is also advisable to avoid extremely hot or cold places, maintaining a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, round, film-coated tablet

Package unit

PTP - 28 tablets/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.